TY -的T1及儿童呼吸系统药物的处方JF -欧洲呼吸杂志》乔欧元和J SP - 310 LP - 313 - 10.1183 / 09031936.04.00015404六世- 23 - 2非盟- t郑大世,G.W.盟——大羚羊,非盟主义者——Sturkenboom M.C.J.M. AU - van den安加,J.N. AU -斯特里克,B.H.C. Y1 - 2004/02/01 UR - //www.qdcxjkg.com/content/23/2/310.abstract N2 -许多呼吸系统药物配方不适合婴幼儿。疗效和安全性研究大多局限于年龄较大的儿童。然而，儿童经常使用呼吸道药物治疗常见疾病，如哮喘、上呼吸道和下呼吸道感染、鼻炎和鼻窦炎。研究了儿童呼吸道药物的未经许可和超说明书使用情况。利用综合初级保健信息项目中的计算机化医疗记录进行了一项基于人群的队列研究。研究人群包括1998年在全科医生注册的所有0-16岁儿童的随机样本。在研究期间，所有呼吸系统药物的处方都根据其许可和超说明书状态进行了分类。研究人群包括13426名患者(51.7%为男性，中位年龄8.7岁)，其中2502人(19%)在1998年接受了5253份呼吸道药物处方。共有3,306张(62.9%)处方涉及持牌药物。在剩余的1947个处方(37.1%)中，882个(16.8%)是无证儿童使用，1065个(20.3%)是超说明书处方。 The 1‐yr cumulative risk of receiving an unlicensed or off-label prescription was 45% among children with at least one prescription for a respiratory drug. This population-based study showed that a large proportion of respiratory drugs prescribed by the general practitioner are unlicensed for use in children, or licensed but prescribed in an off-label manner. Results have to be interpreted with caution because they may unjustly suggest inaccurate prescribing, whereas it may be difficult to treat children with respiratory symptoms and diseases, because for many respiratory drugs paediatric data on safety and efficacy are insufficient. These findings underline the importance of research on suitable formulations, dosages and efficacy of respiratory drugs in children. This work was supported by the Sophia Foundation for Scientific Research through a research grant (SSWO project no. 293). ER -